Access to LARCs Act

HR8084, titled the "Access to LARCs Act," was introduced in the House of Representatives on March 25, 2026, by Rep. Hinson (R-IA) and three cosponsors. The bill has been referred to the House Committee on Energy and Commerce, indicating it is in the early stages of the legislative process. The bill's primary action is to mandate a study by the Secretary of Health and Human Services (HHS) on access to various contraceptive methods at community health centers located in health care deserts. This study will analyze barriers such as reimbursement, inventory, provider training, and patient education. The bill does not contain any provisions for direct funding authorization or appropriation. Its sole mechanism is to direct HHS to conduct a study and subsequently submit a report to Congress within 180 days of the bill's enactment. Therefore, there is no direct money trail to analyze for corporate beneficiaries or specific programs at this stage. The study's findings could potentially inform future legislative actions that might involve funding, but HR8084 itself is a data-gathering initiative. Structural winners, if the bill were to advance and lead to subsequent legislation, could include manufacturers of contraceptive methods, particularly those focused on long-acting reversible contraceptives (LARCs), as well as organizations providing training and educational resources for healthcare providers. However, without any funding or specific policy changes outlined in this bill, these are speculative long-term impacts. Currently, there are no direct corporate beneficiaries or losers. The bill's definition of "contraceptive method" includes drugs, devices, sexual risk avoidance education, and natural family planning, indicating a broad scope for the study. As of April 9, 2026, the bill remains in committee. The next legislative steps would involve committee consideration, potential mark-up, and a vote to report the bill to the full House. Given its early stage and the fact that it mandates a study rather than direct spending or regulation, its immediate market impact is limited. The bill has minimal legislative momentum, with only four sponsors and no companion bill in the Senate.